Co-PIs: Tim Peterson, Luke Gilbert

Our company, Bio-I/O, was recently awarded a phase I STTR grant from the NIGMS to use CRISPRi/a screening to identify drug targets for disease ranging from Alzheimer’s to Type II diabetes.